Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MRGPRX1 | Q96LB2 | 5/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547577 | 1.00 | KDM1A (0.38) | KDM1AMRGPRX1LIPCLIPGPDE2A | |
| SCHEMBL31046841 | 0.90 | MRGPRX1 (0.38) | KDM1AMRGPRX1LIPCLIPGACLY | |
| SCHEMBL23877585 | 0.90 | MRGPRX1 (0.38) | KDM1AMRGPRX1LIPCLIPGACLY | |
| SCHEMBL23877624 | 0.85 | MRGPRX1 (0.38) | KDM1AMRGPRX1LIPCLIPGACLY | |
| SCHEMBL23877610 | 0.85 | KDM1A (0.41) | KDM1ALIPCLIPGACLY | |
| SCHEMBL23877547 | 0.83 | KDM1A (0.35) | KDM1AMRGPRX1LIPCLIPGTSPO | |
| SCHEMBL30547561 | 0.83 | KDM1A (0.35) | KDM1AMRGPRX1LIPCLIPGTSPO | |
| SCHEMBL22820229 | 0.81 | KDM1A (0.40) | KDM1ALIPCLIPGACLY | |
| SCHEMBL26188612 | 0.81 | LIPC (0.35) | LIPCLIPGPDE2A | |
| SCHEMBL23877527 | 0.81 | KDM1A (0.39) | KDM1ALIPCLIPGACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | KDM1A 2735/4885MRGPRX1 1500/4885LIPC 2934/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | KDM1A 2735/4885MRGPRX1 1500/4885LIPC 2934/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | KDM1A 4072/4885MRGPRX1 2156/4885LIPC 1288/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | KDM1A 2735/4885MRGPRX1 1500/4885LIPC 2934/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | KDM1A 2735/4885MRGPRX1 1500/4885LIPC 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.